重新调整用途
药物重新定位
业务
风险分析(工程)
政府(语言学)
更安全的
临床试验
药品
药物开发
投资(军事)
医学
公共经济学
药理学
精算学
经济
计算机科学
计算机安全
工程类
政治学
哲学
病理
政治
法学
语言学
废物管理
作者
Alejandro Schcolnik‐Cabrera,Daniel Juárez-López,Alfonso Dueñas‐González
标识
DOI:10.2174/0929867327666200831141337
摘要
Complex common diseases are a significant burden for our societies and demand not only preventive measures but also more effective, safer, and more affordable treatments. The whole process of the current model of drug discovery and development implies a high investment by the pharmaceutical industry, which ultimately impact in high drug prices. In this sense, drug repurposing would help meet the needs of patients to access useful and novel treatments. Unlike the traditional approach, drug repurposing enters both the preclinical evaluation and clinical trials of the compound of interest faster, budgeting research and development costs, and limiting potential biosafety risks. The participation of government, society, and private investors is needed to secure the funds for experimental design and clinical development of repurposing candidates to have affordable, effective, and safe repurposed drugs. Moreover, extensive advertising of repurposing as a concept in the health community, could reduce prescribing bias when enough clinical evidence exists, which will support the employment of cheaper and more accessible repurposed compounds for common conditions.
科研通智能强力驱动
Strongly Powered by AbleSci AI